@ShionogiUS profile picture
Shionogi Inc. (U.S.) @ShionogiUS

Shionogi Inc. is a U.S. subsidiary of Shionogi & Co., Ltd., a Japanese research-driven pharmaceutical company. Community guidelines here: bit.ly/3Ozijf0

Joined October 2022
  • Tweets 141
  • Following 84
  • Followers 417
124 Photos and videos
#News: The FDA has approved our oral antiviral for post-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older. It is the first and only oral option to help prevent COVID-19 following exposure to an infected individual. Learn more here: tinyurl.com/bdhbwb2v
2
7
22
3,323
Addressing unmet challenges has long been central to our work in rare disease. This #ALSAwarenessMonth, we reaffirm our commitment to the ALS community as we continue to learn, listen, and stay focused on the work ahead. shionogi.com
0:10
4
352
Aeron Hurt, PhD, Vice President, Global Medical Science, shares thoughts about the @NEJM publication of our Phase 3 study evaluating our investigational oral antiviral for the prevention of COVID-19 following exposure to an infected individual. Learn more: shionogi.com/us/en/news/2026…
1
7
170
#BREAKINGNEWS: @NEJM has published results from our SCORPIO-PEP clinical trial, the first and only Phase 3 study of an investigational oral antiviral to meet the primary endpoint of preventing symptomatic COVID-19 following exposure to an infected individual. #InfectiousDisease #COVID19 Learn more: shionogi.com/us/en/news/2026…
1
8
13
404
Antibiotics are a cornerstone of modern medicine, but antibiotic innovation hasn't kept pace with the rise of antibiotic-resistant infections. In this @Nature supplement, Gareth Morgan explores economic solutions to drive antibiotic innovation. nature.com/articles/d41586-0…
1
1
174
United by the message that "Together We Are Strong," Shionogi recognizes #InternationalPompeDay on April 15 by raising awareness and supporting early diagnosis of #PompeDisease through efforts like newborn screening. #TogetherWeAreStrong
1
209
#News: @BARDA has awarded Shionogi Inc. a new contract to advance our #antibiotic against biothreats and drug-resistant pathogens. Initially funded at $119M with options up to $482M, this contract also supports a new U.S. manufacturing site and procurement. shionogi.com/us/en/news/2026…
1
2
245
It's a new chapter for Shionogi in the U.S. and Canada! Today we completed the acquisition of all rights to an FDA-approved treatment for amyotrophic lateral sclerosis (ALS) and welcomed more than 100 new team members to Shionogi Inc. Learn more: shionogi.com/us/en/news/2026…
3
221
The first patients have been enrolled in Esprit, our global Phase 2 clinical trial for adults with late-onset Pompe disease (#LOPD). This is an important step in our work to advance potential new options for people living with #PompeDisease. Learn more here: shionogi.com/us/en/news/2026…
203
New data from a retrospective analysis presented at #CROI2026 found COVID-19 exacerbated and worsened or led to new chronic cardiovascular, neurological, respiratory and renal conditions.
1
229
We're kicking off #RareDisease Month at the @WORLDSymposia, an annual research conference dedicated to #LysosomalDiseases, including #PompeDisease.​ Find out about our global Phase 2 clinical study in Pompe disease at espritstudy.com and let us know if you'll be at #WORLDSymposium.
250
We are expanding and solidifying our commitment to rare disease with the planned acquisition of global rights to Tanabe Pharma’s FDA-approved treatment for ALS. Until the deal closes on or around April 1, 2026, business activities will continue as usual. shionogi.com/us/en/news/2025…
4
784
#News: Our parent company completed the acquisition of Japan Tobacco Inc.’s (JT) pharmaceutical business. As part of this transaction, the NJ-based Akros Pharma Inc., formerly a subsidiary of JT, has become a subsidiary of Shionogi Inc. shionogi.com/us/en/news/2025…
259
At @IDWeekmtg, we will present new data from the SENTRY Antimicrobial Surveillance Program, examining in vitro activity of our antibiotic against high-priority Gram-negative clinical isolates. Join for presentation 627 on 10/22 at 1:57pm ET. Read more: shionogi.com/us/en/news/2025…
1
309
This year at @IDWeekmtg we’re presenting new data from PROVE, an extensive medical chart review study designed to evaluate the safety and effectiveness of our antibiotic in adult patients with serious infections caused by certain Gram-negative pathogens. Read more: shionogi.com/us/en/news/2025…
1
232
#News Gareth Morgan will become President of Qpex, a Shionogi Group Company, and continue his long and impactful journey with our organization. Dr. @MikeMndudley is retiring and will remain involved as a strategic advisor.
Qpex Biopharma@Qpexbio
15 Oct 2025
#NEWS: We welcome Gareth Morgan, longstanding Shionogi team member and global leader, to Qpex as President. Morgan succeeds @MikeMndudley , Pharm.D., who is retiring and will serve as a strategic advisor to Qpex and Shionogi. Learn more: qpexbio.com/news/gareth-morg…
1
269
The #countdown is on to #IDWeek2025! We’ll be sharing 17 scientific presentations from across our anti-infective programs. Learn more about our plans: shionogi.com/us/en/news/2025…
1
1
297
#BREAKING: The U.S. Food and Drug Administration (#FDA) has accepted a New Drug Application for our investigational oral antiviral for the prevention of COVID-19 following exposure to an infected individual. Learn more: shionogi.com/us/en/news/2025…
3
8
346
#NEWS - Two strategic deals with Japan Tobacco’s Pharmaceutical Business: acquiring Akros Pharma & a tender offer for full ownership of Torii Pharmaceutical. These $1B transactions strengthen our pipeline and drive our global #innovation. Read more: bit.ly/3YzZ6P1
1
5
304
Load more